Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 20/20 | 0.51 |
| ▸ | PIM1 | P11309 | 19/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 12/20 | 0.51 |
| ▸ | CDC7 | O00311 | 9/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 11/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855336 | 0.78 | CSNK2B (0.55) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1851701 | 0.77 | CSNK2B (0.58) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL12661564 | 0.72 | CSNK2B (0.67) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1852831 | 0.71 | PIM1 (0.65) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1852339 | 0.71 | CSNK2B (0.57) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1855436 | 0.71 | CSNK2B (0.62) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1851091 | 0.71 | CSNK2B (0.56) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1851089 | 0.71 | CSNK2B (0.56) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL1856877 | 0.70 | CSNK2B (0.67) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 | |
| SCHEMBL4277571 | 0.70 | CSNK2B (0.64) | CSNK2BPIM1CSNK2A2CDC7CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | CSNK2B 350/4885PIM1 1977/4885CSNK2A2 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.